Your session is about to expire
← Back to Search
Study Summary
This trial looks at the safety & reactions of different combinations of flu, RSV & SARS-CoV-2 vaccines in healthy older people.
- COVID-19
- Respiratory Syncytial Virus
- Influenza
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have not gotten a flu shot in the past 6 months.You are between 50 and 75 years old.Do you think you are generally healthy?You must have received your COVID-19 vaccine at least four months ago, including any booster shots.
- Group 1: mRNA-1230 Dose Level A
- Group 2: mRNA-1045 Dose Level B
- Group 3: mRNA-1045 Dose Level C
- Group 4: mRNA-1273.214
- Group 5: mRNA-1230 Dose Level C
- Group 6: mRNA-1345
- Group 7: mRNA-1230 Dose Level B
- Group 8: mRNA-1010
- Group 9: mRNA-1045 Dose Level A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an opportunity to enroll in the experiment at this time?
"Clinicialtrials.gov's records show that this trial is actively seeking participants, with the original post date of October 14th 2022 and a most recent update on the same day."
What is the total number of research facilities running this clinical investigation?
"Velocity Clinical Research in Anderson, South carolina; Family Practice of West Volusia, P.A. in DeLand Georgia and Southeast Regional Research Group in Columbus Texas are amongst the sites participating this clinical trial as well as an additional 9 locations."
Has the FDA provided authorization for administration of mRNA-1045 Dose Level B?
"The safety of mRNA-1045 Dose Level B was assigned a score of 1 due to this being Phase I trial with limited clinical evidence regarding efficacy and safety."
Who is eligible to partake in this research?
"This research project is currently recruiting 675 adults afflicted with influenza, aged between 50 and 75. To qualify for the program, participants must be capable of fulfilling all mandated follow-up protocols; they need to have a body mass index ranging from 18–35 kg/m2; non-pregnant female volunteers are obligated to abstain from any activity that may lead to pregnancy or use some form of contraception over the course of four months; additionally, applicants should have received at least one dose (primary series or booster) of an authorized vaccine against COVID-19 more than 120 days prior to Day 1 (or less per local guidance"
Does this medical trial include individuals aged 75 and above?
"This clinical trial seeks participants aged 50 and above, yet below the age of 75."
What is the population size of this research initiative?
"This clinical trial necessitates 675 participants that meet the inclusion criteria. Those interested in joining can do so from either Velocity Clinical Research located in Anderson, South carolina or Family Practice of West Volusia P.A., which is situated in DeLand, Georgia."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Research Centers of America (cenexel): < 24 hours
- DM Clinical Research: < 24 hours
- Atlanta Center for Medical Research - Family Medicine: < 24 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger